clinical trial · NCT06477419
A Study of Sacituzumab Govitecan in People With Mesothelioma
MesotheliomaMesotheliomas PleuralMesothelioma; PleuraSacituzumab govitecan-hziy
brief summary
Participants will receive sacituzumab govitecan until their disease gets worse (progresses), they have severe side effects and cannot continue study treatment, or the participants or the study doctor thinks it's in your best interest to stop treatment.
started
Jun 21, 2024
primary completion
Jun 21, 2029
completion
Jun 21, 2029
last updated
Jul 15, 2025
official title
Phase 2 Study of Sacituzumab Govitecan-hziy in Patients With Previously Treated Mesothelioma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol